从2027年1月1日起, Novo Nordisk将美国对Ozempic和Wegovy的价格削减50%, 以便在竞争中提高可负担性。 Novo Nordisk cuts U.S. prices for Ozempic and Wegovy by up to 50% starting Jan. 1, 2027, to boost affordability amid competition.

从2027年1月1日起, Novo Nordisk将美国Ozempic和Wegovy的市价削减50%, 将月价定为675美元, Ozempic下降35%, Wegovy降低50%, Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by up to 50% starting January 1, 2027, setting the monthly price at $675, a 35% drop for Ozempic and 50% for Wegovy, with reductions also applying to the pill forms of Wegovy and Rybelsus. 这一行动与降低的医疗保险价格相一致,并反映了GLP-1药物市场日益加剧的竞争和定价压力。 The move aligns with lower Medicare prices and reflects growing competition and pricing pressure in the GLP-1 drug market. 该公司说,改革的目的是在转向现金支付式保健模式的同时,提高病人和支付者的可负担性。 The company said the changes aim to improve affordability for patients and payers amid a shift toward cash-pay healthcare models.